Revance Therapeutics (RVNC) Misses Q1 EPS by 9c

Revance Therapeutics (NASDAQ: RVNC) reported Q1 EPS of ($0.94), $0.09 worse than the analyst estimate of ($0.85). Revenue for the quarter came in at $75 thousand versus the consensus estimate of $70 thousand.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Stratasys (SSYS) Tops Q2 EPS by 2c ;; Offers Guidance
• Beyond Air, Inc. (XAIR) Tops Q1 reported Q1 Revenue ; Offers Guidance